In both AML models, nestin+ cell depletion at the time of chemotherapy delayed AML recurrence and reduced leukemic blasts in circulation or infiltrating the spleen (Figures 4B and S2H–S2K). The gene discussed is NES; the disease is acute myeloid leukemia.